Recursion Secures US$50 Million Investment from Nvidia to Accelerate AI-Driven Drug Discovery
IndustryTrends
To accelerate the training of Recursion AI models for drug development, Nvidia committed $50 million.
Using its own biological and chemical datasets, Recursion will train AI models on the cloud platform of Nvidia.
Through BioNeMo, Nvidia could then license the AI models to biotech companies.
Earlier this year, it broadly released a cloud-based generative AI tool for drug research.
Recursion intends to support its pipeline as well as present and potential partners using Nvidia's technologies.
Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp
_____________
Disclaimer: Analytics Insight does not provide financial advice or guidance on cryptocurrencies and stocks. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. This article is provided for informational purposes and does not constitute investment advice. You are responsible for conducting your own research (DYOR) before making any investments. Read more about the financial risks involved here.